Globe and Mail features Providence Therapeutics in column, ‘Now we know why we need a vaccine industry in Canada'

Ontario Industry Updates
Written By Maura Campbell
Providence therapeutics.png

The Globe and Mail featured a column this week by Campbell Clark which featured Providence Therapeutics and argued why investing in made-in-Canada vaccines is important. Providence Therapeutics will be presenting at this year’s OBIO Investment Summit.

Maura Campbell
Previous

The Globe and Mail highlights RBC's investment in new Lumira venture fund
Next

Satellos Receives $1 Million Investment from Parent Project Muscular Dystrophy